Application Note Biopharma/Pharma Rituximab Biosimilar Analysis Using the Agilent InfinityLab Pro iQ Plus LC/MS Author Abstract Ravindra Gudihal Agilent Technologies, Inc. The biotherapeutics field is rapidly expanding, with recombinant monoclonal antibodies (mAbs) emerging as key products, particularly in the development…
Key words
innovator, mass, biosimilars, daltons, abundance, glycoform, rituximab, infinitylab, charge, intact, time, plus, relative, mabs, molecular